Skip to main content
SpringerLink
Log in

What Is the Curative Potential of Refractory Leukemia with Related and Unrelated Allogeneic Transplants?

  • Chapter
Current Controversies in Bone Marrow Transplantation

Part of the book series: Current Clinical Oncology ((CCO))

Abstract

Acute leukemia was uniformly fatal until the development of effective therapeutic chemotherapy (CT) regimens in the early 1970s. Combination CT for acute leukemia induced complete remission (CR) in the majority of patients, but postremission therapy was inadequate to prevent relapse (1). Relapsed patients, and those who failed to achieve CR, invariably died from their leukemia.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 84.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 109.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Rosenthal DS and Moloney WC. Treatment of acute granulocytic leukemia in adults, N. Engl. J. Med., 277 (1992) 1176–1177.

    Google Scholar 

  2. Thomas ED, Buckner CD, Banaji M One hundred patients with acute leukemia treated by chemotherapy, total body irradiation, and allogeneic bone marrow transplantation, Blood, 49 (1977) 511–533.

    PubMed  CAS  Google Scholar 

  3. Thomas ED. Marrow transplantation for malignant diseases, J. Clin. Oncol., 1 (1983) 517–531.

    PubMed  CAS  Google Scholar 

  4. Stone RM and Mayer RJ. Treatment of the newly diagnosed adult with de novo acute myeloid leukemia, Hematol. Oncol. Clin N. Am., 7 (1993) 47–64.

    CAS  Google Scholar 

  5. Hoelzer D. Treatment of acute lymphoblastic leukemia, Semin. Hematol., 31 (1994) 1–15.

    PubMed  CAS  Google Scholar 

  6. Hines JD, Oken MM, Mazza JJ High-dose cytosine arabinoside and m-AMSA is effective therapy in relapsed acute nonlymphocytic leukemia, J. Clin. Oncol., 2 (1984) 545–549.

    PubMed  CAS  Google Scholar 

  7. Herzig RH, Lazarus HM, Wolff SN High-dose cytosine arabinoside therapy with and without anthracycline antibiotics for remission reinduction of acute nonlymphoblastic leukemia, J. Clin. Oncol., 3 (1985) 992–997.

    PubMed  CAS  Google Scholar 

  8. Freund M, Diedrich H, Ganser A Treatment of relapsed or refractory adult acute lymphocytic leukemia, Cancer, 69 (1992) 709–716.

    Article  PubMed  CAS  Google Scholar 

  9. Milpied N, Gisselbrecht C, Harousseau JL Successful treatment of adult acute lymphoblastic leukemia after relapse with prednisone, intermediate-dose cytarabine, mitoxantrone, and etoposide (FAME) chemotherapy, Cancer, 66 (1990) 627–631.

    Article  PubMed  CAS  Google Scholar 

  10. Giona F, Testi AM, Annino L Treatment of primary refractory and relapsed acute lymphoblastic leukaemia in children and adults: the GIMEMA/AIEOP experience. Gruppo Italiano Malattie Ematologiche Maligne dell’Adulto. Associazione Italiana Ematologia ed Ocologia Pediatrica, Br. J. Haematol., 86 (1994) 55–61.

    Article  PubMed  CAS  Google Scholar 

  11. Archimbaud E, Thomas X, Leblond V Timed sequential chemotherapy for previously treated patients with acute myeloid leukemia: long-term follow-up of the etoposide, mitoxantrone, and cytarabine-86 trial, J. Clin. Oncol., 13 (1995) 11–18.

    PubMed  CAS  Google Scholar 

  12. Estey E. Treatment of refractory AML, Leukemia, 10 (1996) 932–936.

    PubMed  CAS  Google Scholar 

  13. Copelan EA, McGuire EA. The biology and treatment of acute lymphoblastic leukemia in adults, Blood, 85 (1995) 1151–1168.

    PubMed  CAS  Google Scholar 

  14. Appelbaum FR. Allogeneic hematopoietic stem cell transplantation for acute leukemia, Semin. Oncol., 24 (1997) 114–123.

    PubMed  CAS  Google Scholar 

  15. Champlin R, Gale RP. Acute myelogenous leukemia: recent advances in therapy, Blood, 69 (1987) 1551–1562.

    PubMed  CAS  Google Scholar 

  16. Schiller GJ. Treatment of resistant disease, Leukemia, 12 (1998) S20 - S24.

    PubMed  CAS  Google Scholar 

  17. Wiernik PH, Banks PL, Case DC Jr Cytarabine plus idarubicin or daunorubicin as induction and consolidation therapy for previously untreated adult patients with acute myeloid leukemia, Blood, 79 (1992) 313–319.

    PubMed  CAS  Google Scholar 

  18. Vogler WR, Velez-Garci E, Weiner RS A phase III trial comparing idarubicin and daunorubicin in combination with cytarabine in acute myelogenous leukemia: a Southeastern Cancer Study Group Study, J. Clin. Oncol., 10 (1992) 1103–1111.

    PubMed  CAS  Google Scholar 

  19. Berman E, Heller G, Santorsa J Results of a randomized trial comparing idarubicin and cytosine arabinoside with daunorubicin and cytosine arabinoside in adult patients with newly diagnosed acute myelogenous leukemia, Blood, 77 (1991) 1666–1674.

    PubMed  CAS  Google Scholar 

  20. Forman SJ, Schmidt GM, Nademanee AP Allogeneic bone marrow transplantation for primary induction failure for patients with acute leukemia, J. Clin. Oncol., 9 (1991) 1570–1574.

    PubMed  CAS  Google Scholar 

  21. Mehta J, Powles R, Horton C Bone marrow transplantation for primary refractory acute leukemia, Bone Marrow Transplant., 14 (1994) 415–418.

    PubMed  CAS  Google Scholar 

  22. Biggs JC, Horowitz MM, Gale RP Bone marrow transplants may cure patients with acute leukemia never achieving remission with chemotherapy, Blood, 80 (1992) 1090–1093.

    PubMed  CAS  Google Scholar 

  23. Drobyski WR, Endean DJ, Klein JP Detection of BCR/ABL RNA transcripts using the polymerase chain reaction is highly predictive for relapse in patients transplanted with unrelated marrow grafts for chronic myelogenous leukaemia, Br. J. Haematol., 98 (1997) 458–466.

    Article  PubMed  CAS  Google Scholar 

  24. Hochhaus A, Reiter A, Skladny H Molecular monitoring of residual disease in chronic myelogenous leukemia patients after therapy, Recent Results Cancer Res., 144 (1998) 36–45.

    Article  PubMed  CAS  Google Scholar 

  25. Porter DL, Roth MS, Lee SJ Adoptive immunotherapy with donor mononuclear cell infusions to treat relapse of acute leukemia or myelodysplasia after allogeneic bone marrow transplantation, Bone Marrow Transplant., 18 (1996) 975–980.

    PubMed  CAS  Google Scholar 

  26. Fefer A, Robinson N, Benyunes MC Interleukin-2 therapy after bone marrow or stem cell transplantation for hematologic malignancies, Cancer J. Sci. Am., 3 (1997) S48–53.

    PubMed  Google Scholar 

  27. Bonin C, Ferrari G, Verzeletti S HSV-TK gene transfer into donor lymphocytes for control of allogeneic graft-versus-leukemia, Science, 276 (1997) 1719–1724.

    Article  Google Scholar 

  28. Appelbaum FR, Clift RA, Buckner CD Allogeneic marrow transplantation for acute nonlymphoblastic leukemia after first relapse, Blood, 61 (1983) 949–953.

    PubMed  CAS  Google Scholar 

  29. Clift RA, Buckner CD, Thomas ED The treatment of acute nonlymphoblastic leukemia by allogeneic bone marrow transplantation, Bone Marrow Transplant., 2 (1987) 243–258.

    PubMed  CAS  Google Scholar 

  30. Clift RA, Buckner CD, Appelbaum FR Allogeneic marrow transplantation during untreated first relapse of acute leukemia, J. Clin. Oncol., 10 (1992) 1723–1729.

    PubMed  CAS  Google Scholar 

  31. Weiden PL, Flournoy N, Thomas ED Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts, N. Engl. J. Med., 300 (1979) 1068–1073.

    Article  PubMed  CAS  Google Scholar 

  32. Schmitz N, Gassmann W, Rister M Fractionated total body irradiation and high-dose VP 16213 followed by allogeneic bone marrow transplantation in advanced leukemias, Blood, 72 (1988) 1567–1573.

    PubMed  CAS  Google Scholar 

  33. Herzig RH, Boffin MM, Barrett AJ Bone-marrow transplantation in high-risk acute lymphoblastic leukaemia in first and second remission, Lancet, 1 (1987) 786–789.

    Article  PubMed  CAS  Google Scholar 

  34. Dinsmore R, Kirkpatrick D, Flomenberg N Allogeneic bone marrow transplantation for patients with acute nonlymphocytic leukemia, Blood, 63 (1984) 649–656.

    PubMed  CAS  Google Scholar 

  35. Dinsmore R, Kirkpatrick D, Flomenberg N Allogeneic bone marrow transplantation for patients with acute lymphoblastic leukemia, Blood, 62 (1983) 381–388.

    PubMed  CAS  Google Scholar 

  36. Wingard JR, Piantadosi S, Santos GW Allogeneic bone marrow transplantation for patients with high-risk acute lymphoblastic leukemia, J. Clin. Oncol., 8 (1990) 820–830.

    PubMed  CAS  Google Scholar 

  37. Kernan NA, Bartsch G, Ash RC Analysis of 462 transplantations from unrelated donors facilitated by the National Marrow Donor Program, N. Engl. J. Med., 328 (1993) 593–602.

    Article  PubMed  CAS  Google Scholar 

  38. Schiller G, Feig SA, Territo M Treatment of advanced acute leukaemia with allogeneic bone marrow from unrelated donors, Br. J. Haematol., 88 (1994) 72–78.

    Article  PubMed  CAS  Google Scholar 

  39. Sierra J, Storer B, Hansen JA Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose, Blood, 89 (1997) 4226–4235.

    PubMed  CAS  Google Scholar 

  40. Laport GF, Larson RA. Treatment of adult acute lymphoblastic leukemia, Semi. Oncol., 24 (1997) 70–82.

    CAS  Google Scholar 

  41. Blume KG, Beutler E, Bross KJ Bone-marrow ablation and allogeneic marrow transplantation in acute leukemia, N. Engl. J. Med., 302 (1980) 1041–1046.

    Article  PubMed  CAS  Google Scholar 

  42. Doney K, Fisher LD, Appelbaum FR Treatment of acute lymphoblastic leukemia with allogeneic bone marrow transplantation. Multivariate analysis of factors affecting acute graft-versus-host-disease, relapse, and relapse-free survival, Bone Marrow Transplant., 7 (1991) 453–459.

    PubMed  CAS  Google Scholar 

  43. Szydlo R, Goldman JM, Klein JP Results of allogeneic bone marrow transplants for leukemia using donors other than HLA-identical siblings, J. Clin. Oncol., 15 (1997) 1767–1777.

    PubMed  CAS  Google Scholar 

  44. Nademanee A, Schmidt GM, Parker P The outcome of matched unrelated donor bone marrow transplantation in patients with hematologic malignancies using molecular typing for donor selection and graft-versus-host disease prophylaxis regimen of cyclosporine, methotrexate, and prednisone, Blood, 86 (1995) 1228–1234.

    PubMed  CAS  Google Scholar 

  45. Geller RB, Devine SM, O’Toole K Allogeneic bone marrow transplantation with matched unrelated donors for patients with hematologic malignancies using a preparative regimen of high-dose cyclophosphamide and fractionated total body irradiation, Bone Marrow Transplant., 20 (1997) 219–225.

    Article  PubMed  CAS  Google Scholar 

  46. Sierra J, Storer B, Hansen JA Transplantation of marrow cells from unrelated donors for treatment of high-risk acute leukemia: the effect of leukemic burden, donor HLA-matching, and marrow cell dose, Blood, 89 (1997) 4226–4235.

    PubMed  CAS  Google Scholar 

  47. Storb R, Deeg HJ, Whitehead J Methotrexate and cyclosporine compared with cyclosporine alone for prophylaxis of acute graft versus host disease after marrow transplantation for leukemia, N. Engl. J. Med., 314 (1986) 729–735.

    Article  PubMed  CAS  Google Scholar 

  48. Horowitz MM Gale RP, Sondel PM Graft-versus-leukemia reactions after bone marrow transplantation, Blood,75 (1990) 555–562.

    Google Scholar 

  49. Marmont AM, Horowitz MM, Gale RP T-cell depletion of HLA-identical transplants in leukemia, Blood, 78 (1991) 2120–2130.

    PubMed  CAS  Google Scholar 

  50. Soiffer RI, Fairclough D, Robertson M CD6-depleted allogeneic bone marrow transplantation for acute leukemia in first complete remission, Blood, 89 (1997) 3039–3047.

    PubMed  CAS  Google Scholar 

  51. Papadopoulos EB, Carabasi MH, Castro-Malaspina H T-cell-depleted allogeneic bone marrow transplantation as postremission therapy for acute myelogenous leukemia: freedom from relapse in the absence of graft-versus-host disease, Blood, 91 (1998) 1083–1090.

    PubMed  CAS  Google Scholar 

  52. Jansen J, Hanks S, Akard L Selective T cell depletion with CD8-conjugated magnetic beads in the prevention of graft-versus-host disease after allogeneic bone marrow transplantation, Bone Marrow Transplant., 15 (1995) 271–278.

    PubMed  CAS  Google Scholar 

  53. Gale RP, Horowitz MM, Ash RC Identical-twin bone marrow transplants for leukemia, Ann. Intern. Med., 120 (1994) 646–652.

    PubMed  CAS  Google Scholar 

  54. Kolb HJ, Schattenberg A, Goldman JM Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. European Group for Blood and Marrow Transplantation Working Party Chronic Leukemia, Blood, 86 (1995) 2041–2050.

    PubMed  CAS  Google Scholar 

  55. Collins RH Jr, Shpilberg O, Drobyski WR Donor leukocyte infusions in 140 patients with relapsed malignancy after allogeneic bone marrow transplantation, J. Clin. Oncol., 15 (1997) 433–444.

    PubMed  Google Scholar 

  56. Vogelsang GB, Hess AD. Graft-versus-host disease: new directions for a persistent problem, Blood, 84 (1994) 2061–2067.

    PubMed  CAS  Google Scholar 

  57. Champlin R. Graft-versus-leukemia without graft-versus-host disease: an elusive goal of bone marrow transplantation, Semin. Hematol., 29 (1992) 46–52.

    PubMed  CAS  Google Scholar 

  58. Giralt S, Hester J, Huh Y,CD8-depleted donor lymphocyte infusion as treatment for relapsed chronic myelogenous leukemia after allogeneic bone marrow transplantation, Blood,86 (1995) 43374343.

    Google Scholar 

  59. Champlin R, Ho W, Gajewski J Selective depletion of CD8’ T lymphocytes for prevention of graft-versus-host disease after allogeneic bone marrow transplantation, Blood, 76 (1990) 418–423.

    PubMed  CAS  Google Scholar 

  60. Nimer SD, Giorgi J, Gajewski JL Selective depletion of CD8’ cells for prevention of graft-versushost disease after bone marrow transplantation: a randomized trial, Transplantation, 57 (1994) 82–87.

    Article  PubMed  CAS  Google Scholar 

  61. Estey E, Thall P, David C. Design and analysis of trials of salvage therapy in acute myelogenous leukemia, Cancer Chemother. Pharmacol., 40 (1997) S9–12.

    Article  PubMed  Google Scholar 

Download references

Authors
  1. Matt E. Kalaycio MD
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. Bone Marrow Transplant Program, Department of Hematology/Medical Oncology, The Cleveland Clinic Foundation, Cleveland, OH, USA

    Brian J. Bolwell MD (Director, Staff Physician) (Director, Staff Physician)

Rights and permissions

Reprints and permissions

Copyright information

© 2000 Humana Press Inc., Totowa, NJ

About this chapter

Cite this chapter

Kalaycio, M.E. (2000). What Is the Curative Potential of Refractory Leukemia with Related and Unrelated Allogeneic Transplants?. In: Bolwell, B.J. (eds) Current Controversies in Bone Marrow Transplantation. Current Clinical Oncology. Humana Press, Totowa, NJ. https://doi.org/10.1007/978-1-59259-657-7_8

Download citation

  • DOI: https://doi.org/10.1007/978-1-59259-657-7_8

  • Publisher Name: Humana Press, Totowa, NJ

  • Print ISBN: 978-1-4684-9812-7

  • Online ISBN: 978-1-59259-657-7

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation